Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA

Anti-Cancer Drugs

Volumn 24, Issue 6, 2013, Pages 566-576

  Gu, Wen Jun ^a   Liu, Hai Lin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

5 FU; Bax; Bcl 2; E cadherin; gemcitabine; hnRNP A2 B1; MDR1; MMP 2; Oxaliplatin; pancreatic cancer

Indexed keywords

FLUOROURACIL; GELATINASE A; GEMCITABINE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A2; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN B1; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OXALIPLATIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SMALL INTERFERING RNA; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UVOMORULIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL MIGRATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; INDUCTION CHEMOTHERAPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR INVASION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; DEOXYCYTIDINE; DRUG SYNERGISM; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN GROUP A-B; HUMANS; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 84878930441     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283608bc5     Document Type: Article

References (23)

1. Jemal A, Siegel R, Xu J,Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Gu K, Wu CX, Bao PP. Incidence of pancreatic cancer in Shanghai: a current, retrospective and comparative exploration. J Surg Concepts Pract 2009; 14:510.
3. Sheikh R, Walsh N, Clynes M, O'Connor R, McDermott R. Challenges of drug resistance in the management of pancreatic cancer. Expert Rev Anticancer Ther 2010; 10:1647-1661.
4. Squadroni M, Fazio N. Chemotherapy in pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci 2010; 14:386-394.
5. O'Reilly EM, Abou-Alfa GK. Cytotoxic therapy for advanced pancreatic adenocarcionma. Semin Oncol 2007; 34:347-353. (Pubitemid 47176624)
6. Wang L, Liu HL, Li Y, Yuan P. Proteomic analysis of pancreatic intraepithelial neoplasia and pancreatic carcinoma in rat models. World J Gastroenterol 2011; 17:1434-1441.
7. Gu W, Liu W, Shen X, Shi Y,Wang L, Liu H. Emergence of heterogeneous nuclear ribonucleoprotein A2/B1 versus loss of E-cadherin: their reciprocal immunoexpression profiles in human pancreatic cancer. Ann Diagn Pathol 2013; 17:14-17.
8. Martinez-Contreras R, Cloutier P, Shkreta L, Fisette JF, Revil T, Chabot B. hnRNP proteins and splicing control. Adv Exp Med Biol 2007; 623: 123-147.
9. Wu S, Sato M, Endo C, Sakurada A, Dong B, Aikawa H, et al. hnRNP B1 protein may be a possible prognostic factor in squamous cell carcinoma of the lung. Lung Cancer 2003; 41:179-186. (Pubitemid 36842781)
10. Ushigome M, Ubagai T, Fukuda H, Tsuchiya N, Sugimura T, Takatsuka J, et al. Up-regulation of hnRNP A1 gene in sporadic human colorectal cancers. Int J Oncol 2005; 26:635-640.
11. Zhou J, Allred DC, Avis I, Martínez A, Vos MD, Smith L, et al. Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer. Breast Cancer Res Treat 2001; 66: 217-224. (Pubitemid 32675024)
12. Yan-Sanders Y, Hammons GJ, Lyn-Cook BD. Increased expression of heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP) in pancreatic tissue from smokers and pancreatic tumor cells. Cancer Lett 2002; 183:215-220. (Pubitemid 34628426)
13. Lee CH, Lum JH, Cheung BP, Wong MS, Butt YK, Tam MF, et al. Identification of the heterogeneous nuclear ribonucleoprotein A2/B1 as the antigen for the gastrointestinal cancer specific monoclonal antibody MG7. Proteomics 2005; 5:1160-1166. (Pubitemid 40469043)
14. Mayeda A, Munroe SH, Cáceres JF, Krainer AR. Function of conserved domains of hnRNP A1 and other hnRNP A/B proteins. EMBO J 1994; 13:5483-5495. (Pubitemid 24351827)
15. Tauler J, Zudaire E, Liu H, Shih J, Mulshine JL. hnRNP A2/B1 modulates epithelial-mesenchymal transition in lung cancer cell lines. Cancer Res 2010; 70:7137-7147.
16. Boise LH, Gottschalk AR, Quintáns J, Thompson CB. Bcl-2 and Bcl-2 related proteins in apoptosis regulation. Curr Top Microbiol Immunol 1995; 200:107-121.
17. Geyer J, Janko C. Treatment of MDR1 mutant dogs with macrocyclic lactones. Curr Pharm Biotechnol 2012; 13:969-986.
18. Su L, Cheng CY, Mruk DD. Drug transporter, P-glycoprotein (MDR1), is an integrated component of the mammalian blood-testis barrier. Int J Biochem Cell Biol 2009; 41:2578-2587.
19. Aplin AE, Howe A, Alahari SK, Juliano RL. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 1998; 50:197-263. (Pubitemid 28304026)
20. Grabowska MM, Day ML. Soluble E-cadherin: more than a symptom of disease. Front Biosci 2012; 17:1948-1964.
21. Nawrocki-Raby B, Gilles C, Polette M, Bruyneel E, Laronze JY, Bonnet N, et al. Upregulation of MMPs by soluble E-cadherin in human lung tumor cells. Int J Cancer 2003; 105:790-795. (Pubitemid 36706102)
22. Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Methods Mol Biol 2010; 622:471-487.
23. Brigitte Bauvois. New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression. Biochem Biophys Acta, Rev Cancer 2012; 1825:29-36.